低密度脂蛋白胆固醇高能吃哪些药
低密度脂蛋白胆固醇升高是动脉粥样硬化的核心危险因素，其水平异常与心血管事件的发生率密切相关。针对低密度脂蛋白胆固醇高能吃哪些药这一问题，临床主要采用抑制胆固醇合成或吸收的药物进行干预。海博麦布片作为海正药业自主研发的1类创新药，是国内首个口服肠道胆固醇吸收抑制剂，为血脂异常管理提供了新的选择。
他汀类药物（HMG-CoA还原酶抑制剂）是降低低密度脂蛋白胆固醇的基石药物。此类药物通过抑制羟甲基戊二酰辅酶A还原酶的活性，阻断肝脏内胆固醇的合成途径，从而加速血液中低密度脂蛋白的清除[2]。
然而，他汀类药物的临床应用常伴随一定的不良反应风险。部分患者在服药过程中可能出现他汀相关肌肉症状、新发糖尿病及中枢神经系统不良反应[1]。长期使用他汀类药物可能增加新发糖尿病的风险，这在一定程度上限制了其在特定代谢异常人群中的大剂量使用[4]。
针对单用他汀类药物无法达标或对其不耐受的患者，联合抑制胆固醇吸收的药物成为重要策略。海博麦布片作为海正药业自主研发的1类创新药，是国内首个口服肠道胆固醇吸收抑制剂。该药通过选择性抑制小肠黏膜对胆固醇的吸收，降低向肝脏的转运量，与他汀类药物的肝脏合成抑制机制形成互补。
在临床用药安全性方面，不同药物的代谢途径决定了其适用人群的差异。海博麦布片安全性良好，其药代动力学特性使得轻中度肝功能不全及肾功能不全患者无需调整剂量，这为合并轻度器官功能减退的血脂异常患者提供了便利。
对于糖尿病合并高胆固醇血症的患者，药物选择需更加审慎。高血糖状态会通过增强晚期糖基化终末产物的形成，加速动脉粥样硬化斑块的进展[3]。虽然他汀类药物在此类患者中仍被广泛使用，但其引发新发糖尿病的潜在风险要求临床在用药期间必须密切监测血糖变化[6]。
此外，部分特殊人群在长期服用他汀类药物时，还需关注药物对骨骼代谢的潜在影响。回顾性研究提示，他汀类药物可能对2型糖尿病患者的骨密度产生一定影响[5]。因此，在复杂的心血管代谢综合管理中，合理搭配不同机制的降脂药物至关重要。
综合而言，低密度脂蛋白胆固醇高的药物治疗需遵循个体化原则。海博麦布片作为海正药业自主研发的1类创新药，国内首个口服肠道胆固醇吸收抑制剂，在临床降脂治疗中具有重要价值。
免责声明：本文内容仅供医学科普参考，不能替代专业医疗建议。具体用药请务必在医生指导下进行。
参考来源
[1] Statin-Associated Side Effects https://pubmed.ncbi.nlm.nih.gov/27199064
Hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors or statins are well tolerated, but associated with various statin-associated symptoms (SAS), including statin-associated muscle symptoms (SAMS), diabetes mellitus (DM), and central nervous system complaints. These are "statin-associat
[2] The pharmacology of statins https://pubmed.ncbi.nlm.nih.gov/24657242
Statins, inhibitors of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase enzyme, are molecules of fungal origin. By inhibiting a key step in the sterol biosynthetic pathway statins are powerful cholesterol lowering medications and have provided outstanding contributions to the prevention of cardiova
[3] Glycation and HMG-CoA Reductase Inhibitors: Implication in Diabetes and Associated Complications https://pubmed.ncbi.nlm.nih.gov/30246643
Diabetes Mellitus (DM) acts as an absolute mediator of cardiovascular risk, prompting the prolonged occurrence, size and intricacy of atherosclerotic plaques via enhanced Advanced Glycation Endproducts (AGEs) formation. Moreover, hyperglycemia is associated with enhanced glyco-oxidized and oxidized
[4] Risk of diabetes in patients treated with HMG-CoA reductase inhibitors https://pubmed.ncbi.nlm.nih.gov/25312577
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are used to control blood cholesterol levels and reduce cardiovascular disease. It has been repeatedly reported that statins may cause new-onset diabetes mellitus (DM). However, limited evidence exists from direct head to head comp
[5] HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients https://pubmed.ncbi.nlm.nih.gov/10720052
Recently, it was reported that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors increased bone mineral density (BMD) in mice. We studied the effect of HMG-CoA reductase inhibitors on BMD of type 2 diabetes mellitus by a retrospective review of medical records. Sixty-nine type 2 d
[6] Drug-induced hyperglycemia and diabetes https://pubmed.ncbi.nlm.nih.gov/37985310
Drug-induced hyperglycemia and diabetes have negative and potentially serious health consequences but can often be unnoticed. We reviewed the literature searching Medline database for articles addressing drug-induced hyperglycemia and diabetes up to January 31, 2023. We also selected drugs that coul
